

## NICE Technology Appraisals About Medicines: Formulary Adherence

| Technology appraisal (TA)<br>are hyperlinks to full guidance                                                        | Titles     | Date of TA<br>Release                                                                                                                                                                                                                                                                                                                                                           | Availability of medicine for NHS patients with this<br>medical condition, as indicated by NICE | Adherence of local formulary to NICE                                |                         |
|---------------------------------------------------------------------------------------------------------------------|------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------|---------------------------------------------------------------------|-------------------------|
|                                                                                                                     |            |                                                                                                                                                                                                                                                                                                                                                                                 |                                                                                                | Included on the Trust<br>Formulary for this indication<br>Yes OR No | Reason provided if "No" |
| 2000-06                                                                                                             |            |                                                                                                                                                                                                                                                                                                                                                                                 |                                                                                                |                                                                     |                         |
| Attention deficit hyperactivity disorder (ADHD) - methylphenidate, atomoxetine and dexamfetamine (review) (TA98)    | 31/03/2006 | Methylphenidate, atomoxetine, dexamfetamine – recommended options for ADHD; if more than one is appropriate, choose the cheapest.                                                                                                                                                                                                                                               | Yes                                                                                            |                                                                     |                         |
| Hepatitis B (chronic) - adefovir dipivoxil and pegylated interferon alpha-2a (TA96)                                 | 28/02/2006 | Peginterferon alfa-2a – a recommended first line option for chronic hepatitis B.<br>Adefovir dipivoxil – recommended option if peginterferons unsuccessful or not tolerated. Given as monotherapy or with lamivudine depending on lamivudine resistance.                                                                                                                        | Yes                                                                                            |                                                                     |                         |
| Cardiovascular disease - statins (TA94)                                                                             | 31/01/2006 | Statin therapy is recommended for adults with specified clinical evidence of CVD or at specified risk of CVD.                                                                                                                                                                                                                                                                   | Yes                                                                                            |                                                                     |                         |
| Ovarian cancer (advanced) - paclitaxel, pegylated liposomal doxorubicin hydrochloride and topotecan (review) (TA91) | 31/05/2005 | Paclitaxel, liposomal doxorubicin, topotecan – recommended options in advanced disease depending largely upon platinum sensitivity, resistance, tolerance, and allergy.                                                                                                                                                                                                         | No                                                                                             | This medicine is not applicable to C&W                              |                         |
| Gastrointestinal stromal tumours - imatinib (TA86) Partially updated by TA209                                       | 31/10/2004 | Imatinib – recommended first-line for management of people with KIT (CD117)-positive unresectable and/or metastatic GISTs.                                                                                                                                                                                                                                                      | No                                                                                             | This medicine is not applicable to C&W                              |                         |
| Renal transplantation - immuno-suppressive regimens (adults) (TA85)                                                 | 30/09/2004 | Basiliximab, daclizumab – consider for induction therapy with combinations that include ciclosporin.<br>Tacrolimus – an alternative to ciclosporin for initial therapy or maintenance.<br>Mycophenolate mofetil – Only consider when intolerant of calcineurin inhibitors (ciclosporin-like drugs).<br>Sirolimus – not recommended unless intolerant of calcineurin inhibitors. | No                                                                                             | This medicine is not applicable to C&W                              |                         |
| Atopic dermatitis (eczema) - topical steroids (TA81)                                                                | 31/08/2004 | Topical corticosteroid – the cheapest suitable option for atopic eczema should be used and applied no more than twice daily.                                                                                                                                                                                                                                                    | Yes                                                                                            |                                                                     |                         |

|                                                                                                                        |            |                                                                                                                                                                                                                                                                                                                                        |     |                                        |
|------------------------------------------------------------------------------------------------------------------------|------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|----------------------------------------|
| Atopic dermatitis (eczema) - pimecrolimus and tacrolimus (TA82)                                                        | 31/08/2004 | Not recommended for first line use or mild disease. If maximum topical steroids ineffective or threaten important side effects, consider:<br><b>Tacrolimus</b> – for moderate to severe disease in patients over 2 years.<br><b>Pimecrolimus</b> – for moderate disease on face and neck for those between 2 and 16 years.             | Yes |                                        |
| Insomnia - newer hypnotic drugs (TA77)                                                                                 | 30/04/2004 | <b>Zaleplon, zolpidem, zopiclone</b> – prescribe the cheapest of these or a shorter-acting benzodiazepine, for a short period, if non-drug treatments don't work.                                                                                                                                                                      | Yes |                                        |
| Hepatitis C - pegylated interferons, ribavirin and alfa interferon (TA75)<br>Partially updated by TA200; replaces TA14 | 31/01/2004 | <b>Peginterferon alfa with ribavirin</b> – recommended for moderate to severe chronic hepatitis C as specified within this TA .                                                                                                                                                                                                        | Yes |                                        |
| Leukaemia (chronic myeloid) - imatinib (TA70)<br>(partially updated by TA241 and TA251)                                | 31/10/2003 | <b>Imatinib</b> – a recommended option for those who present in the accelerated phase or with blast crisis, or those in chronic phase who progress to these stages without prior imatinib.                                                                                                                                             | Yes |                                        |
| Macular degeneration (age-related) - photodynamic therapy (TA68)                                                       | 30/09/2003 | <b>Verteporfin</b> – recommended for wet ARMD in specified people if classic subfoveal choroidal neovascularisation (CNV), with no sign of occult CNV. Not recommended for wet ARMD with mostly classic and some occult CNV unless in a clinical trial. No recommendation about PDT for ARMD with occult CNV since product unlicensed. | No  | This medicine is not applicable to C&W |
| Non-Hodgkin's lymphoma - rituximab (TA65)                                                                              | 30/09/2003 | <b>Rituximab with CHOP</b> – recommended first line for diffuse large-B-cell lymphoma at stage 2, 3 or 4; in stage 1 only in a clinical trial. Rituximab not recommended without CHOP.                                                                                                                                                 | Yes |                                        |
| Growth hormone deficiency (adults) - human growth hormone (TA64)                                                       | 31/08/2003 | <b>Human growth hormone</b> – recommended only where severe growth hormone deficiency severely affects quality of life.                                                                                                                                                                                                                | Yes |                                        |
| Colorectal cancer - capecitabine and tegafur uracil (TA61)                                                             | 30/05/2003 | <b>Capecitabine or tegafur with uracil (and folinic acid)</b> – recommended among first options for metastatic colorectal cancer.                                                                                                                                                                                                      | No  | This medicine is not applicable to C&W |
| Ovarian cancer - paclitaxel (review) (TA55)<br>Partially updated by TA91                                               | 31/01/2003 | <b>Cisplatin or carboplatin, with or without paclitaxel</b> – recommended as alternatives for first-line use (usually following surgery) in ovarian cancer.                                                                                                                                                                            | Yes |                                        |
| Diabetes (types 1 and 2) - long acting insulin analogues (TA53)                                                        | 31/12/2002 | <b>Insulin glargine</b> – a recommended option for type 1 diabetes. Guidance in type 2 diabetes is contained in the <a href="#">CG66 Update</a> .                                                                                                                                                                                      | Yes |                                        |
| Myocardial infarction - thrombolysis (TA52)                                                                            | 31/10/2002 | <b>Alteplase, reteplase, streptokinase, tenecteplase</b> – suggestions made on how to choose the most appropriate agent in hospitals. Reteplase or tenecteplase recommended for use outside hospitals.                                                                                                                                 | Yes |                                        |

|                                                                                                          |            |                                                                                                                                                                                                                                                                                                                                   |     |                                        |
|----------------------------------------------------------------------------------------------------------|------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|----------------------------------------|
| Acute coronary syndromes - glycoprotein IIb/IIIa inhibitors (review) (TA47)<br>Partially updated by CG94 | 30/09/2002 | A <b>GP IIb/IIIa inhibitor</b> should be considered as an elective PCI adjunct in patients with diabetes, and in patients undergoing specified complex procedures. Not recommended in procedurally uncomplicated elective PCI unless specified complications occur.                                                               | Yes |                                        |
| Arthritis (juvenile idiopathic) - etanercept (TA35)                                                      | 31/03/2002 | <b>Etanercept</b> – recommended for 4–17 year olds with active disease where methotrexate unsuccessful or not tolerated.                                                                                                                                                                                                          | Yes |                                        |
| Asthma (older children) - inhaler devices (TA38)                                                         | 31/03/2002 | Inhaler choice should reflect patient needs:<br><b>Steroids</b> – press-and-breathe inhalers with a spacer recommended first line.<br><b>Bronchodilators</b> – a wider choice of inhalers, including easily portable ones.                                                                                                        | Yes |                                        |
| Breast cancer - trastuzumab (TA34)                                                                       | 31/03/2002 | In metastatic breast cancer with HER2 at 3+:<br><b>Trastuzumab with paclitaxel</b> – recommended if no prior chemo and anthracyclines inappropriate.<br><b>Trastuzumab monotherapy</b> – recommended after at least two other regimens tried including at least one anthracycline, taxane, and hormonal treatment if appropriate. | No  | This medicine is not applicable to C&W |
| Multiple sclerosis - beta interferon and glatiramer acetate (TA32)                                       | 31/01/2002 | <b>Beta interferon, glatiramer</b> – recommendation to use these medicines not justified.                                                                                                                                                                                                                                         | Yes |                                        |
| Leukaemia (lymphocytic) - fludarabine (TA29)                                                             | 31/01/2002 | <b>Fludarabine</b> – recommended option orally instead of CHOP, VAP or CVP regimens in B-cell CLL if first chemo regimen unsuccessful or not tolerated. Use infusion only if oral route not suitable.                                                                                                                             | Yes |                                        |
| Pancreatic cancer - gemcitabine (TA25)                                                                   | 30/05/2001 | <b>Gemcitabine</b> – a first line option for advanced or metastatic disease if Karnofsky score 50 or more, if curative surgery not an option. Not for second line use.                                                                                                                                                            | Yes |                                        |
| Brain cancer - temozolomide (TA23)                                                                       | 30/04/2001 | <b>Temozolomide</b> – consider for specified people with recurrent brain cancer if initial chemo failed or not tolerated. Only for first line use in a clinical trial.                                                                                                                                                            | No  | This medicine is not applicable to C&W |
| Motor neurone disease - riluzole (TA20)                                                                  | 31/01/2001 | <b>Riluzole</b> – should be available for MND.                                                                                                                                                                                                                                                                                    | Yes |                                        |
| Asthma (children under 5) - inhaler devices (TA10)                                                       | 31/08/2000 | <b>Steroids, bronchodilators</b> – deliver by a pressurised metered dose inhaler with spacer, using a facemask if necessary. If this not suitable, consider a nebuliser, or a dry powder inhaler in the over 3s.                                                                                                                  | Yes |                                        |